FDA
-
-
-
-
-
-
-
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm²
-
-
-
-
-
-
-
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis
-
-
-
-
-
-
-
Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth
-
-
-
-
-
-
-
Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
-
-
-
-
-
-
-
Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

